{"id":746310,"date":"2023-04-10T16:04:14","date_gmt":"2023-04-10T20:04:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/"},"modified":"2023-04-10T16:04:14","modified_gmt":"2023-04-10T20:04:14","slug":"aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/","title":{"rendered":"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO and TORONTO, April  10, 2023  (GLOBE NEWSWIRE) &#8212; Aptose Biosciences Inc. (\u201cAptose\u201d or the \u201cCompany\u201d) (NASDAQ: APTO, TSX: APS),\u00a0a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.<\/p>\n<p align=\"justify\">The Aptose management team will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, or to access the panel presentation, please contact your Canaccord Genuity conference representative.<\/p>\n<p align=\"justify\">\n        <strong>Canaccord Genuity\u2019s Horizons in Oncology Conference<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%\">Panel Title:<\/td>\n<td style=\"max-width:85%;width:85%;min-width:85%\">\n            <em>New &amp; Better Approaches for Oncology Targets<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td>Date:<\/td>\n<td>Thursday, April 20, 2023<\/td>\n<\/tr>\n<tr>\n<td>Presentation Time:<\/td>\n<td>2:00 \u2013 2:45 PM<\/td>\n<\/tr>\n<tr>\n<td>Format:<\/td>\n<td>Panel presentation moderated by John Newman, Ph.D., Biotechnolgy Analyst<\/td>\n<\/tr>\n<tr>\n<td>Participant:<\/td>\n<td>Dr. William Rice, Chairman, President and Chief Executive Officer, Aptose<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About Aptose<\/strong>\n      <\/p>\n<p align=\"justify\">Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company&#8217;s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1\/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a\/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t-DSlxMeKKdhfk6ckg-QyyEeODIuBcw9AMVp__L6OaPKcBq19v1X0hCSxmbNkgLhfQsy7jLVoxAdeZP5NaTzKA==\" rel=\"nofollow noopener\" target=\"_blank\">www.aptose.com<\/a>.<\/p>\n<p align=\"justify\">For further information, please contact:<\/p>\n<table style=\"border-collapse: collapse;width:70%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>Aptose Biosciences Inc.<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>LifeSci Advisors, LLC<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Susan Pietropaolo<\/td>\n<td>Dan Ferry, Managing Director<\/td>\n<\/tr>\n<tr>\n<td>Investor Relations<\/td>\n<td>617-430-7576<\/td>\n<\/tr>\n<tr>\n<td>201-923-2049<\/td>\n<td>Daniel@LifeSciAdvisors.com<\/td>\n<\/tr>\n<tr>\n<td>spietropaolo@aptose.com<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDQ0ZjU4OTItYjIzMC00Y2E5LTk4MDgtYTViZWViYmEyMTdkLTEwMzkyNTM=\/tiny\/Aptose-Biosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) &#8212; Aptose Biosciences Inc. (\u201cAptose\u201d or the \u201cCompany\u201d) (NASDAQ: APTO, TSX: APS),\u00a0a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference on April 20, 2023. The Aptose management team will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, or to access the panel presentation, please contact your Canaccord Genuity conference representative. Canaccord Genuity\u2019s Horizons in Oncology Conference Panel Title: New &amp; Better Approaches for Oncology Targets Date: Thursday, April 20, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746310","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) &#8212; Aptose Biosciences Inc. (\u201cAptose\u201d or the \u201cCompany\u201d) (NASDAQ: APTO, TSX: APS),\u00a0a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference on April 20, 2023. The Aptose management team will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, or to access the panel presentation, please contact your Canaccord Genuity conference representative. Canaccord Genuity\u2019s Horizons in Oncology Conference Panel Title: New &amp; Better Approaches for Oncology Targets Date: Thursday, April 20, &hellip; Continue reading &quot;Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-10T20:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference\",\"datePublished\":\"2023-04-10T20:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/\",\"name\":\"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=\",\"datePublished\":\"2023-04-10T20:04:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference - Market Newsdesk","og_description":"SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) &#8212; Aptose Biosciences Inc. (\u201cAptose\u201d or the \u201cCompany\u201d) (NASDAQ: APTO, TSX: APS),\u00a0a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference on April 20, 2023. The Aptose management team will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, or to access the panel presentation, please contact your Canaccord Genuity conference representative. Canaccord Genuity\u2019s Horizons in Oncology Conference Panel Title: New &amp; Better Approaches for Oncology Targets Date: Thursday, April 20, &hellip; Continue reading \"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-10T20:04:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference","datePublished":"2023-04-10T20:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/","name":"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=","datePublished":"2023-04-10T20:04:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDg5NyM1NTE4MjE3IzIwMjcyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptose-to-participate-in-canaccord-genuitys-2023-horizons-in-oncology-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aptose to Participate in Canaccord Genuity\u2019s 2023 Horizons in Oncology Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746310"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746310\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}